colorectal neoplasms

Summary

Summary: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.

Top Publications

  1. ncbi Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer
    M M Borner
    Early Clinical Studies Group of The European Organization for Research and Treatment of Cancer, Belgium
    Eur J Cancer 38:349-58. 2002
  2. ncbi Role of miR-143 targeting KRAS in colorectal tumorigenesis
    X Chen
    Jiangsu Diabetes Center, State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, China
    Oncogene 28:1385-92. 2009
  3. pmc Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer
    Veronica Rodilla
    Institut d Investigació Biomèdica de Bellvitge Gran Via km 2 7, Hospitalet and Institut Municipal d Investigacions Mèdiques Hospital del Mar, Dr Aiguader 88, 08003 Barcelona, Spain
    Proc Natl Acad Sci U S A 106:6315-20. 2009
  4. ncbi Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer
    Pierre Laurent-Puig
    INSERM UMR S775 Molecular Basis of Xenobiotics Response, Paris, France
    J Clin Oncol 27:5924-30. 2009
  5. pmc Identification of key genes for carcinogenic pathways associated with colorectal adenoma-to-carcinoma progression
    Anke H Sillars-Hardebol
    Department of Pathology Tumor Profiling Unit, VU University Medical Center, De Boelelaan 1117, 1081HV, Amsterdam, The Netherlands
    Tumour Biol 31:89-96. 2010
  6. ncbi Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    Herbert Hurwitz
    Duke University, Durham, NC, USA
    N Engl J Med 350:2335-42. 2004
  7. ncbi The consensus coding sequences of human breast and colorectal cancers
    Tobias Sjoblom
    Ludwig Center and Howard Hughes Medical Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Science 314:268-74. 2006
  8. ncbi Estimates of cancer incidence and mortality in Europe in 2008
    J Ferlay
    International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France
    Eur J Cancer 46:765-81. 2010
  9. ncbi Identification of c-MYC as a target of the APC pathway
    T C He
    Howard Hughes Medical Institute and Johns Hopkins Oncology Center, 424 North Bond Street, Baltimore, MD 21231, USA
    Science 281:1509-12. 1998
  10. ncbi Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland
    P Lichtenstein
    Department of Medical Epidemiology, Karolinska Institute, Stockholm, Sweden
    N Engl J Med 343:78-85. 2000

Detail Information

Publications261 found, 100 shown here

  1. ncbi Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer
    M M Borner
    Early Clinical Studies Group of The European Organization for Research and Treatment of Cancer, Belgium
    Eur J Cancer 38:349-58. 2002
    ..v. 5-FU/LV. Oral UFT/LV compares favourably with i.v. 5-FU/LV in terms of toxicity and patient's preference and leads to prolonged 5-FU exposure, which is comparable to continuous i.v. 5-FU treatment...
  2. ncbi Role of miR-143 targeting KRAS in colorectal tumorigenesis
    X Chen
    Jiangsu Diabetes Center, State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, China
    Oncogene 28:1385-92. 2009
    ..Taken together, the present study provides the first evidences that miR-143 is significant in suppressing colorectal cancer cell growth through inhibition of KRAS translation...
  3. pmc Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer
    Veronica Rodilla
    Institut d Investigació Biomèdica de Bellvitge Gran Via km 2 7, Hospitalet and Institut Municipal d Investigacions Mèdiques Hospital del Mar, Dr Aiguader 88, 08003 Barcelona, Spain
    Proc Natl Acad Sci U S A 106:6315-20. 2009
    ..The Notch-specific genetic signature is sufficient to block differentiation and promote vasculogenesis in tumors whereas proliferation depends on both pathways...
  4. ncbi Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer
    Pierre Laurent-Puig
    INSERM UMR S775 Molecular Basis of Xenobiotics Response, Paris, France
    J Clin Oncol 27:5924-30. 2009
    ..However, only half of these patients will benefit from treatment, suggesting the need to identify additional biomarkers for cetuximab-based treatment efficacy...
  5. pmc Identification of key genes for carcinogenic pathways associated with colorectal adenoma-to-carcinoma progression
    Anke H Sillars-Hardebol
    Department of Pathology Tumor Profiling Unit, VU University Medical Center, De Boelelaan 1117, 1081HV, Amsterdam, The Netherlands
    Tumour Biol 31:89-96. 2010
    ....
  6. ncbi Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    Herbert Hurwitz
    Duke University, Durham, NC, USA
    N Engl J Med 350:2335-42. 2004
    ..Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclinical and clinical activity against metastatic colorectal cancer, particularly in combination with chemotherapy...
  7. ncbi The consensus coding sequences of human breast and colorectal cancers
    Tobias Sjoblom
    Ludwig Center and Howard Hughes Medical Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Science 314:268-74. 2006
    ..These data define the genetic landscape of two human cancer types, provide new targets for diagnostic and therapeutic intervention, and open fertile avenues for basic research in tumor biology...
  8. ncbi Estimates of cancer incidence and mortality in Europe in 2008
    J Ferlay
    International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France
    Eur J Cancer 46:765-81. 2010
    ..9%). The most common causes of death from cancer were lung cancer (342,000 deaths, 19.9% of the total), colorectal cancer (212,000 deaths, 12.3%), breast cancer (129,000, 7.5%) and stomach cancer (117,000, 6.8%)...
  9. ncbi Identification of c-MYC as a target of the APC pathway
    T C He
    Howard Hughes Medical Institute and Johns Hopkins Oncology Center, 424 North Bond Street, Baltimore, MD 21231, USA
    Science 281:1509-12. 1998
    ..These results provide a molecular framework for understanding the previously enigmatic overexpression of c-MYC in colorectal cancers...
  10. ncbi Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland
    P Lichtenstein
    Department of Medical Epidemiology, Karolinska Institute, Stockholm, Sweden
    N Engl J Med 343:78-85. 2000
    ..The contribution of hereditary factors to the causation of sporadic cancer is unclear. Studies of twins make it possible to estimate the overall contribution of inherited genes to the development of malignant diseases...
  11. ncbi Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
    Jerome Galon
    INSERM U 255, Paris, 75006 France Université Paris Descartes Paris 5, Faculte de Medecine, Paris, 75006 France
    Science 313:1960-4. 2006
    ..In situ analysis of tumor-infiltrating immune cells may therefore be a valuable prognostic tool in the treatment of colorectal cancer and possibly other malignancies...
  12. ncbi Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
    Wendy De Roock
    Centre for Human Genetics, KU Leuven, Leuven, Belgium
    Lancet Oncol 11:753-62. 2010
    ....
  13. ncbi Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening
    E K O Ng
    Institute of Digestive Disease, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, China
    Gut 58:1375-81. 2009
    ..MicroRNAs (miRNAs) have been shown to offer great potential in the diagnosis of cancer. We investigated whether plasma miRNAs could discriminate between patients with and without colorectal cancer (CRC)...
  14. ncbi Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer
    Eric Van Cutsem
    University Hospital Gasthuisberg, Digestive Oncology Unit, Herestraat 49, 3000 Leuven, Belgium
    N Engl J Med 360:1408-17. 2009
    ....
  15. ncbi Colorectal cancer
    David Cunningham
    Gastrointestinal Unit, Royal Marsden Hospital National Health Service Foundation Trust, London and Surrey, UK
    Lancet 375:1030-47. 2010
    ..However, biomarker development is essential to aid selection of patients likely to respond to therapy, thereby rationalising treatments and improving outcomes...
  16. ncbi Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study
    Jean Yves Douillard
    Centre Rene Gauducheau, Nantes, France
    J Clin Oncol 28:4697-705. 2010
    ....
  17. ncbi MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer
    I A Asangani
    Department of Experimental Surgery and Molecular Oncology of Solid Tumors, Medical Faculty Mannheim, University of Heidelberg, Germany
    Oncogene 27:2128-36. 2008
    ..This is the first study to show that Pdcd4 is negatively regulated by miR-21. Furthermore, it is the first report to demonstrate that miR-21 induces invasion/intravasation/metastasis...
  18. ncbi The genomic landscapes of human breast and colorectal cancers
    Laura D Wood
    Ludwig Center for Cancer Genetics and Therapeutics and Howard Hughes Medical Institute at Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA
    Science 318:1108-13. 2007
    ..These results have implications for understanding the nature and heterogeneity of human cancers and for using personal genomics for tumor diagnosis and therapy...
  19. pmc Phenotypic characterization of human colorectal cancer stem cells
    Piero Dalerba
    Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA
    Proc Natl Acad Sci U S A 104:10158-63. 2007
    ..These results validate the stem cell working model in human CRC and provide a highly robust surface marker profile for CRC stem cell isolation...
  20. pmc Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data
    M P Coleman
    Cancer Research UK Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK
    Lancet 377:127-38. 2011
    ..This is the first study in a programme to investigate international survival disparities, with the aim of informing health policy to raise standards and reduce inequalities in survival...
  21. ncbi Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status
    Eric Van Cutsem
    University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
    J Clin Oncol 29:2011-9. 2011
    ..An updated survival analysis, including additional patients analyzed for tumor mutation status, was undertaken...
  22. ncbi High frequency of mutations of the PIK3CA gene in human cancers
    Yardena Samuels
    Sidney Kimmel Comprehensive Cancer Center, Howard Hughes Medical Institute, The Johns Hopkins University Medical Institutions, Baltimore, MD 21231, USA
    Science 304:554. 2004
  23. ncbi Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study
    Leonard B Saltz
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, Room H 917, New York, NY 10021, USA
    J Clin Oncol 26:2013-9. 2008
    ....
  24. pmc The colorectal microRNAome
    Jordan M Cummins
    The Sidney Kimmel Comprehensive Cancer Center and Howard Hughes Medical Institute, Johns Hopkins University Medical Institutions, Baltimore, MD 21231, USA
    Proc Natl Acad Sci U S A 103:3687-92. 2006
    ..These studies suggest that the human genome contains many more miRNAs than currently identified and provide an approach for the large-scale experimental cloning of novel human miRNAs in human tissues...
  25. pmc Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
    Sandra Misale
    Laboratory of Molecular Genetics, Institute for Cancer Research and Treatment, 10060 Candiolo Torino, Italy
    Nature 486:532-6. 2012
    ....
  26. ncbi Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer
    Zhaohui Huang
    Department of Pathology, Cancer Hospital, Fudan University, Shanghai, China
    Int J Cancer 127:118-26. 2010
    ..773 with 73.0% sensitivity and 79.7% specificity in discriminating advanced adenomas. Collectively, these data suggest that plasma miR-29a and miR-92a have strong potential as novel noninvasive biomarkers for early detection of CRC...
  27. pmc Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion
    Adam J Bass
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Nat Genet 43:964-8. 2011
    ..This study shows previously unidentified levels of genomic rearrangements in colorectal carcinoma that can lead to essential gene fusions and other oncogenic events...
  28. ncbi Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer
    Jolien Tol
    Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    N Engl J Med 360:563-72. 2009
    ..We studied the effect of adding the anti-epidermal growth factor receptor (EGFR) antibody cetuximab to a combination of capecitabine, oxaliplatin, and bevacizumab for metastatic colorectal cancer...
  29. ncbi Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology
    Bernard Levin
    The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Gastroenterology 134:1570-95. 2008
    ..It is the strong opinion of these 3 organizations that colon cancer prevention should be the primary goal of screening...
  30. ncbi Systematic review of microsatellite instability and colorectal cancer prognosis
    S Popat
    MRCP, Institute of Cancer Research, Brookes Lawley Building, Sutton, Surrey SM2 5NG, UK
    J Clin Oncol 23:609-18. 2005
    ..To derive a more precise estimate of the prognostic significance of MSI, we have reviewed and pooled data from published studies...
  31. ncbi Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk
    Malcolm G Dunlop
    Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council MRC Human Genetics Unit, Edinburgh, UK
    Nat Genet 44:770-6. 2012
    ..2 (rs5934683, near SHROOM2; P = 7.30 × 10(-10)) This brings the number of independent loci associated with CRC risk to 20 and provides further insight into the genetic architecture of inherited susceptibility to CRC...
  32. ncbi CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer
    Daniel J Weisenberger
    Department of Surgery, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California 90089 9176, USA
    Nat Genet 38:787-93. 2006
    ..Sporadic cases of mismatch repair deficiency occur almost exclusively as a consequence of CIMP-associated methylation of MLH1 . We propose a robust new marker panel to classify CIMP+ tumors...
  33. pmc Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates
    Brenda K Edwards
    Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland 20892 8315, USA
    Cancer 116:544-73. 2010
    ....
  34. ncbi Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen
    Eric Van Cutsem
    University Hospital Gasthuisberg, Leuven, Belgium
    J Clin Oncol 30:3499-506. 2012
    ....
  35. ncbi Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200
    Bruce J Giantonio
    University of Pennsylvania, Philadelphia, PA, USA
    J Clin Oncol 25:1539-44. 2007
    ..This study was conducted to determine the effect of bevacizumab (at 10 mg/kg) on survival duration for oxaliplatin-based chemotherapy in patients with previously treated metastatic colorectal cancer...
  36. ncbi Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33
    Richard S Houlston
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, UK
    Nat Genet 42:973-7. 2010
    ..33 (rs4925386, OR = 0.93, P = 1.89 × 10⁻¹⁰). In addition to identifying new CRC risk loci, this analysis provides evidence that additional CRC-associated variants of similar effect size remain to be discovered...
  37. ncbi Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
    Jaafar Bennouna
    institut de cancérologie de l Ouest, Nantes, France
    Lancet Oncol 14:29-37. 2013
    ..We assessed continued use of bevacizumab plus standard second-line chemotherapy in patients with metastatic colorectal cancer progressing after standard first-line bevacizumab-based treatment...
  38. ncbi Effector memory T cells, early metastasis, and survival in colorectal cancer
    Franck Pages
    INSERM UNITE 255, René Descartes Faculté de Médecine, Assistance Publique Hopitaux de Paris, Cordeliers Biomedical Research Center, University Paris 6, Paris, France
    N Engl J Med 353:2654-66. 2005
    ..The role of tumor-infiltrating immune cells in the early metastatic invasion of colorectal cancer is unknown...
  39. pmc Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth
    Sergei I Grivennikov
    Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine, University of California, San Diego, La Jolla, California 92093 0723, USA
    Nature 491:254-8. 2012
    ..Both early and late colorectal neoplasms exhibit defective expression of several barrier proteins...
  40. ncbi Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial
    Jacques E Rossouw
    Division of Women s Health Initiative, National Heart, Lung, and Blood Institute, 6705 Rockledge Dr, One Rockledge Ctr, Suite 300, Bethesda, MD 20817
    JAMA 288:321-33. 2002
    ..Despite decades of accumulated observational evidence, the balance of risks and benefits for hormone use in healthy postmenopausal women remains uncertain...
  41. ncbi Molecular genetics of colorectal cancer
    Eric R Fearon
    The Cancer Center, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, 48109 2200, USA
    Annu Rev Pathol 6:479-507. 2011
    ....
  42. pmc Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma
    Mauro Castellarin
    BC Cancer Agency, Michael Smith Genome Sciences Centre, Vancouver, British Columbia V5Z 1L3, Canada
    Genome Res 22:299-306. 2012
    ..5 × 10(-6)), and we observed a positive association with lymph node metastasis...
  43. ncbi K-ras mutations and benefit from cetuximab in advanced colorectal cancer
    Christos S Karapetis
    Flinders Medical Centre and Flinders University, Adelaide, Australia
    N Engl J Med 359:1757-65. 2008
    ..The mutation status of the K-ras gene in the tumor may affect the response to cetuximab and have treatment-independent prognostic value...
  44. ncbi Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer
    Carsten Bokemeyer
    University Hospital, Hamburg Eppendorf, Hamburg Eppendorf, Germany
    J Clin Oncol 27:663-71. 2009
    ..The influence of KRAS mutation status was investigated...
  45. ncbi Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression
    Thomas Brabletz
    Department of Pathology, University of Erlangen, Krankenhausstr 8 10, 91054 Erlangen, Germany
    Nat Rev Cancer 5:744-9. 2005
    ..We suggest an extended, integrated model that is consistent with all aspects of human tumour progression - the 'migrating cancer stem (MCS)-cell' concept...
  46. pmc Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues
    E Bandres
    Laboratory of Pharmacogenomics, Cancer Research Program Center for Applied Medical Research, University of Navarra, Navarra, Spain
    Mol Cancer 5:29. 2006
    ..In addition, the expression level of miR-31 was correlated with the stage of CRC tumor. Our results suggest that miRNA expression profile could have relevance to the biological and clinical behavior of colorectal neoplasia...
  47. ncbi A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer
    J Randolph Hecht
    David Geffen School of Medicine at UCLA, Santa Monica, CA 90404, USA
    J Clin Oncol 27:672-80. 2009
    ..This trial evaluated panitumumab added to bevacizumab and chemotherapy (oxaliplatin- and irinotecan-based) as first-line treatment for mCRC...
  48. ncbi Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
    Rafael G Amado
    Amgen, Inc, One Amgen Center Dr, MS 38 2 B, Thousand Oaks, CA 91320 1799, USA
    J Clin Oncol 26:1626-34. 2008
    ..Although activating mutations in KRAS, a small G-protein downstream of EGFR, correlate with poor response to anti-EGFR antibodies in mCRC, their role as a selection marker has not been established in randomized trials...
  49. pmc Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths
    Ann G Zauber
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    N Engl J Med 366:687-96. 2012
    ..In the National Polyp Study (NPS), colorectal cancer was prevented by colonoscopic removal of adenomatous polyps. We evaluated the long-term effect of colonoscopic polypectomy in a study on mortality from colorectal cancer...
  50. ncbi Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab
    Sabine Tejpar
    Digestive Oncology Unit, University Hospital Gasthuisberg, Herestraat 49, Leuven, Belgium B 3000
    J Clin Oncol 30:3570-7. 2012
    ..We investigated in the first-line setting our previous finding that patients with chemorefractory KRAS G13D-mutated metastatic colorectal cancer (mCRC) benefit from cetuximab treatment...
  51. ncbi Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer
    Hiromu Suzuki
    Division of Tumor Biology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, 1650 Orleans Street, Baltimore, Maryland 21231, USA
    Nat Genet 36:417-22. 2004
    ....
  52. ncbi Classification of colorectal cancer based on correlation of clinical, morphological and molecular features
    J R Jass
    Department of Pathology, McGill University, Montreal, Canada
    Histopathology 50:113-30. 2007
    ..This approach to the classification of CRC should accelerate understanding of causation and will impact on clinical management in the areas of both prevention and treatment...
  53. ncbi ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis
    Trude H Agesen
    Department of Cancer Prevention, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Nydalen, Oslo, Norway
    Gut 61:1560-7. 2012
    ..The present study aimed to develop a gene expression classifier for improved risk stratification of patients with stage II CRC...
  54. pmc Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21
    Albert Tenesa
    Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and MRC Human Genetics Unit, Edinburgh EH4 2XU, UK
    Nat Genet 40:631-7. 2008
    ..008) and rs4939827 (P < 0.009). Carrying all six possible risk alleles yielded OR = 2.6 (95% CI = 1.75-3.89) for CRC. These findings extend our understanding of the role of common genetic variation in CRC etiology...
  55. ncbi Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer
    Marc Peeters
    University Hospital Ghent, Ghent, Belgium
    J Clin Oncol 28:4706-13. 2010
    ..This trial evaluated the efficacy and safety of panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone after failure of initial treatment for mCRC by tumor KRAS status...
  56. ncbi Increasing incidence of colorectal cancer in Asia: implications for screening
    Joseph J Y Sung
    Institute of Digestive Diseases, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong
    Lancet Oncol 6:871-6. 2005
    ..Non-polypoidal (flat or depressed) lesions and colorectal neoplasms arising without preceding adenoma (de novo cancers) seem to be more common in Asian than in other ..
  57. ncbi KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
    Wendy De Roock
    Centre for Human Genetics, Catholic University of Leuven, Leuven, Belgium
    Lancet Oncol 12:594-603. 2011
    ..We review the role of mutations in genes other than KRAS on the efficacy of anti-EGFR therapy, and discuss strategies to target these oncogenic alterations alone or in combination with receptor tyrosine-kinase inhibition...
  58. pmc Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
    Timothy S Maughan
    School of Medicine, Cardiff University, Cardiff, UK
    Lancet 377:2103-14. 2011
    ....
  59. ncbi Colorectal cancer
    Jurgen Weitz
    Department of Surgery, University of Heidelberg, Heidelberg, Germany
    Lancet 365:153-65. 2005
    ..Further clinical progress will largely depend on the broader implementation of multidisciplinary treatment strategies following the principles of evidence-based medicine...
  60. ncbi Hereditary colorectal cancer
    Henry T Lynch
    Department of Preventive Medicine and Public Health, Creighton University School of Medicine, Omaha, Nebr 68178, USA
    N Engl J Med 348:919-32. 2003
  61. ncbi Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer
    Minoru Toyota
    First Department of Internal Medicine, Cancer Research Institute, Sapporo Medical University, Sapporo, Japan
    Cancer Res 68:4123-32. 2008
    ..Our results suggest that miR-34b/c and BTG4 are novel tumor suppressors in CRC and that the miR-34b/c CpG island, which bidirectionally regulates miR-34b/c and BTG4, is a frequent target of epigenetic silencing in CRC...
  62. pmc Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer
    Richard S Houlston
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, UK
    Nat Genet 40:1426-35. 2008
    ..1 (rs10411210, RHPN2; P = 4.6 x 10(-9)) and 20p12.3 (rs961253; P = 2.0 x 10(-10)). These findings underscore the value of large sample series for discovery and follow-up of genetic variants contributing to the etiology of CRC...
  63. ncbi Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial
    Wendy S Atkin
    Department of Surgery and Cancer, Imperial College London, London, UK
    Lancet 375:1624-33. 2010
    ..We tested the hypothesis that only one flexible sigmoidoscopy screening between 55 and 64 years of age can substantially reduce colorectal cancer incidence and mortality...
  64. pmc Towards the human colorectal cancer microbiome
    Julian R Marchesi
    School of Biosciences, Cardiff University, Cardiff, United Kingdom
    PLoS ONE 6:e20447. 2011
    ....
  65. ncbi Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
    Wendy De Roock
    Center for Human Genetics, University of Leuven, Leuven, Belgium
    JAMA 304:1812-20. 2010
    ..Patients with metastatic colorectal cancer who have KRAS codon 12- or KRAS codon 13-mutated tumors are presently excluded from treatment with the anti-epidermal growth factor receptor monoclonal antibody cetuximab...
  66. pmc mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways
    Pat Gulhati
    Department of Surgery, University of Kentucky, Lexington, KT, USA
    Cancer Res 71:3246-56. 2011
    ..These findings provide the rationale for including mTOR kinase inhibitors, which inhibit both mTORC1 and mTORC2, as part of the therapeutic regimen for CRC patients...
  67. ncbi Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III)
    Hans Joachim Schmoll
    Department of Internal Medicine IV, Hematology and Oncology, University Clinic Halle Saale, Martin Luther University Halle Wittenberg, Ernst Grube Str 40, 06120 Halle, Germany
    J Clin Oncol 30:3588-95. 2012
    ....
  68. ncbi A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3
    Ian P M Tomlinson
    Molecular and Population Genetics Laboratory, London Research Institute, Cancer Research UK, London WC2A 3PX, UK
    Nat Genet 40:623-30. 2008
    ..3 (P = 3.3 x 10(-18) overall; P = 9.6 x 10(-17) replication), which tags a plausible causative gene, EIF3H. These data provide further evidence for the 'common-disease common-variant' model of CRC predisposition...
  69. ncbi Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology
    Bernard Levin
    The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    CA Cancer J Clin 58:130-60. 2008
    ..It is the strong opinion of these 3 organizations that colon cancer prevention should be the primary goal of screening...
  70. pmc Microsatellite instability in colorectal cancer
    C Richard Boland
    GI Cancer Research Laboratory, Division of Gastroenterology, Department of Internal Medicine, Sammons Cancer Center and Baylor Research Institute, Baylor University Medical Center, Dallas, Texas, USA
    Gastroenterology 138:2073-2087.e3. 2010
    ..Discovery of MSI in colorectal tumors has increased awareness of the diversity of colorectal cancers and implications for specialized management of patients...
  71. doi Transcriptome profile of human colorectal adenomas
    Jacob Sabates-Bellver
    Institute of Molecular Cancer Research, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland
    Mol Cancer Res 5:1263-75. 2007
    ....
  72. pmc Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer
    J Joshua Smith
    Department of Surgery, Vanderbilt Medical Center, Nashville, TN, USA
    Gastroenterology 138:958-68. 2010
    ..We used a gene expression profile derived from invasive, murine colon cancer cells that were highly metastatic in an immunocompetent mouse model to identify patients with colon cancer at risk of recurrence...
  73. ncbi Role of BAX in the apoptotic response to anticancer agents
    L Zhang
    Howard Hughes Medical Institute, Oncology Center, and Program in Human Genetics, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Science 290:989-92. 2000
    ..These results establish an unambiguous role for BAX in apoptotic processes in human epithelial cancers and may have implications for cancer chemoprevention strategies...
  74. ncbi ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer
    Gershon Y Locker
    American Society of Clinical Oncology Tumor Markers Expert Panel, Alexandria, VA 22314, USA
    J Clin Oncol 24:5313-27. 2006
    ..To update the recommendations for the use of tumor marker tests in the prevention, screening, treatment, and surveillance of gastrointestinal cancers...
  75. pmc The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer
    Mark M Pomerantz
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Nat Genet 41:882-4. 2009
    ..These data provide strong support for a biological mechanism underlying this non-protein-coding risk variant...
  76. ncbi Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer
    Francesca Molinari
    Institute of Pathology, Locarno, Switzerland
    Clin Cancer Res 17:4901-14. 2011
    ..We evaluated whether highly sensitive methods for KRAS investigation improve the accuracy of predictions of anti-EGFR MoAbs efficacy...
  77. ncbi American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]
    Douglas K Rex
    Indiana University Medical Center, IU Hospital, Indianapolis 46202, USA
    Am J Gastroenterol 104:739-50. 2009
    ....
  78. ncbi Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer
    O Slaby
    Departments of Clinical and Experimental Pathology, Masaryk Memorial Cancer Institute, Masaryk University, Brno, Czech Republic
    Oncology 72:397-402. 2007
    ..MicroRNAs (miRNAs) are endogenously expressed regulatory noncoding RNAs. Previous, mainly preclinical studies showed altered expression levels of several miRNAs in CRC...
  79. ncbi The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling
    Sari Tuupanen
    Department of Medical Genetics, Genome Scale Biology Research Program, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland
    Nat Genet 41:885-90. 2009
    ..Our work provides evidence that the common CRC predisposition associated with 8q24 arises from enhanced responsiveness to Wnt signaling...
  80. ncbi A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk
    Peter Broderick
    Section of Cancer Genetics, Institute of Cancer Research, Sutton SM2 5NG, UK
    Nat Genet 39:1315-7. 2007
    ..Across the four sample sets, the association between rs4939827 and CRC was highly statistically significant (P(trend) = 1.0 x 10(-12))...
  81. ncbi Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
    C Bokemeyer
    Department of Oncology, Hematology, BMT With Section Pneumology, University Hospital, Hamburg Eppendorf, Germany
    Ann Oncol 22:1535-46. 2011
    ....
  82. ncbi Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer
    Paul Salama
    School of Surgery and Biostatistics Unit, Cancer Trials, Western Australian Institute for Medical Research, University of Western Australia, Australia
    J Clin Oncol 27:186-92. 2009
    ..To determine the prognostic significance of FOXP3(+) lymphocyte (Treg) density in colorectal cancer compared with conventional histopathologic features and with CD8(+) and CD45RO(+) lymphocyte densities...
  83. ncbi Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer
    Timothy J Price
    The Queen Elizabeth Hospital, Woodville, SA 5011 Australia
    J Clin Oncol 29:2675-82. 2011
    ....
  84. ncbi The role of cyclooxygenases in inflammation, cancer, and development
    C S Williams
    Department of Medicine, The Vanderbilt Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee 37232 2279, USA
    Oncogene 18:7908-16. 1999
    ..The in vivo mechanism by which COX-2 affects tumor growth has not been determined. It is possible that both tumor and stromally derived COX-2 could influence tumor angiogenesis and/ or immune function...
  85. ncbi Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene
    L K Su
    Molecular Genetics Laboratory, Johns Hopkins University School of Medicine, Baltimore, MD 21231
    Science 256:668-70. 1992
    ..Sequence comparison of mApc between normal and Min-affected mice identified a nonsense mutation, which cosegregated with the Min phenotype. This mutation is analogous to those found in FAP kindreds and in sporadic colorectal cancers...
  86. pmc Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases
    Eddie K Abdalla
    Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Surg 239:818-25; discussion 825-7. 2004
    ..To examine recurrence and survival rates for patients treated with hepatic resection only, radiofrequency ablation (RFA) plus resection or RFA only for colorectal liver metastases...
  87. ncbi The ABC of APC
    N S Fearnhead
    Cancer and Immunogenetics Laboratory, Imperial Cancer Research Fund, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, UK
    Hum Mol Genet 10:721-33. 2001
    ..This review deals with our understanding to date of how mutations in the APC gene translate into changes at the protein level, which in turn contribute to the role of APC in tumorigenesis...
  88. pmc Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis
    Francesc Balaguer
    Department of Internal Medicine, Division of Gastroenterology, Charles A Sammons Cancer Center and Baylor Research Institute, Baylor University Medical Center, Dallas, Texas 75246, USA
    Cancer Res 70:6609-18. 2010
    ..Methylation silencing of miR-137 in colorectal adenomas suggests it to be an early event, which has prognostic and therapeutic implications...
  89. ncbi DNA methylation markers in colorectal cancer
    Myoung Sook Kim
    Department of Otolaryngology, Head and Neck Surgery, The Johns Hopkins University School of Medicine, 1550 Orleans Street, CRB II 5M, Baltimore, MD, 21231, USA
    Cancer Metastasis Rev 29:181-206. 2010
    ..Therefore, the aim of this review is to understand DNA methylation as a driving force in colorectal neoplasia and its emerging value as a molecular marker in the clinic...
  90. ncbi Association of genetic polymorphisms in ESR2, HSD17B1, ABCB1, and SHBG genes with colorectal cancer risk
    J Sainz
    Division of Molecular Genetic Epidemiology, German Cancer Research Center, Im Neuenheimer Feld 580, 69120 Heidelberg, Germany
    Endocr Relat Cancer 18:265-76. 2011
    ..93, P trend=0.003) in the pooled sample. These findings implicate a role of ESR2 in the risk for developing CRC in women and suggest that HSD17B1, ABCB1, and SHBG genes may contribute to sex steroid-mediated effects on CRC development...
  91. ncbi Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force
    Evelyn P Whitlock
    Kaiser Permanente Center for Health Research, Portland, Oregon, USA
    Ann Intern Med 149:638-58. 2008
    ....
  92. ncbi Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group
    David G Jayne
    Academic Unit of Surgery, St James s University Hospital, Leeds, United Kingdom
    J Clin Oncol 25:3061-8. 2007
    ..Few data are available on rectal cancer, and long-term data on survival and recurrence are now required...
  93. ncbi Folate and colorectal cancer: an evidence-based critical review
    Young In Kim
    Department of Medicine and Nutritional Sciences, Medical Sciences Building, University of Toronto, 1 King s College Circle, Toronto, Ontario, Canada
    Mol Nutr Food Res 51:267-92. 2007
    ..inhibitory effect whereas folate supplementation has a promoting effect on the progression of established colorectal neoplasms. In contrast, folate deficiency in normal colorectal mucosa appears to predispose it to neoplastic ..
  94. ncbi Dietary fiber and colorectal cancer risk: a nested case-control study using food diaries
    Christina C Dahm
    Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK
    J Natl Cancer Inst 102:614-26. 2010
    ..Results of epidemiological studies of dietary fiber and colorectal cancer risk have not been consistent, possibly because of attenuation of associations due to measurement error in dietary exposure ascertainment...
  95. pmc Systemic treatment of colorectal cancer
    Brian M Wolpin
    Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
    Gastroenterology 134:1296-310. 2008
    ....
  96. ncbi Trends in colorectal cancer test use in the medicare population, 1998-2005
    Anna P Schenck
    The Carolinas Center for Medical Excellence, Cary, North Carolina 27518 8598, USA
    Am J Prev Med 37:1-7. 2009
    ..Colorectal cancer (CRC) screening has been covered under the Medicare program since 1998. No prior study has addressed the question of the completeness of CRC screening in the entire Medicare cohort...
  97. pmc Treatment in advanced colorectal cancer: what, when and how?
    I Chau
    Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, UK
    Br J Cancer 100:1704-19. 2009
    ..In this review, we have focused on the implications of these trial results on the everyday management decisions of treating advanced CRC...
  98. ncbi Chemotherapy for colorectal cancer in the metastatic and adjuvant setting: past, present and future
    Ami Sabharwal
    Cancer Research UK, Medical Oncology Unit, Churchill Hospital, Oxford, UK
    Expert Rev Anticancer Ther 7:477-87. 2007
    ..The evolution of chemotherapy use, current practice in the metastatic and adjuvant setting and possible future directions are discussed...
  99. ncbi Critical evaluation of current treatments in metastatic colorectal cancer
    Alan Venook
    Division of Medical Oncology, Clinical Research Office, University of California Cancer Center, Box 1705, 1600 Divisadero, San Francisco, California 94115 1705, USA
    Oncologist 10:250-61. 2005
    ..This review discusses the role of the individual agents in the treatment of mCRC and identifies the most effective regimens...
  100. ncbi The advanced adenoma as the primary target of screening
    Sidney J Winawer
    Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Medical College of Cornell University, New York, New York 10021, USA
    Gastrointest Endosc Clin N Am 12:1-9, v. 2002
    ....

Research Grants75

  1. MOLECULAR CLONING OF HLA CLASS II TUMOR ANTIGENS
    Dorothee Herlyn; Fiscal Year: 2003
    ..The antigens also may be of diagnostic value. ..
  2. Mechanisms of tumor suppressor gene reactivation in colon cancer by berries
    Li Shu Wang; Fiscal Year: 2013
    ..We now propose to evaluate the anthocyanins in berries for their ability to demethylate and reactivate tumor suppressor genes in colon cancer. ..
  3. Gene-Targeted Pro-Drug Therapy for Colorectal Cancer
    Hiremagalur N Jayaram; Fiscal Year: 2013
    ..Therefore, this grant proposal is highly relevant to Veterans Health Care since colorectal cancer is estimated to claim 50,000 Veteran lives in 2010. ..
  4. Fatty acid desaturase activity, fish oil and colorectal cancer chemoprevention
    Harvey J Murff; Fiscal Year: 2013
    ..the cyclo-oxygenase pathway to prostaglandin E2 (PGE2), an inflammatory eicosanoid aberrantly produced in colorectal neoplasms while EPA is converted to the anti-inflammatory prostaglandin E3 (PGE3)...
  5. Clinical Study of Disposition and Biological Activity of d-Limonene
    H H Sherry Chow; Fiscal Year: 2010
    ..This study will help evaluate the potentials of developing limonene as a breast cancer preventive agent. ..
  6. c-Myc transcription in intestinal growth, differentiation, and carcinogenesis
    Gregory S Yochum; Fiscal Year: 2012
    ..Our studies address the fundamental mechanisms underlying b-catenin regulation of normal gastrointestinal development and homeostasis as well as the pathogenesis of intestinal malignancy. ..
  7. Risk reduction through polyamine inhibition among colorectal carcinoma patients
    JASON ZELL; Fiscal Year: 2012
    ....
  8. The Role of the APC Tumor Suppressor Gene in Hematopoiesis and Leukemogenesis
    Zhijian Qian; Fiscal Year: 2013
    ..In this proposal, we plan to determine how APC plays a role in the pathogenesis of MDS and t-MDS/t-AML, ultimately leading to new effective therapeutic strategies for these diseases. ..
  9. COX GENE REGULATION IN INTESTINAL MYOFIBROBLASTS
    Don Powell; Fiscal Year: 2009
    ..abstract_text> ..
  10. Foundations of Pretargeted Radioimmunotherapy
    KARL D WITTRUP; Fiscal Year: 2013
    ..Mathematical modeling and protein biotechnology are essential components of the project. ..
  11. DEVELOPING VIRTUAL COLONOSCOPY FOR CANCER SCREENING
    JEROME Z LIANG; Fiscal Year: 2013
    ..abstract_text> ..
  12. Using vitamin D glucuronide pro-drugs to prevent/treat colon cancer
    JESSE PAUL GOFF; Fiscal Year: 2013
    ..The strength of the current proposal is the ability to target delivery of high concentrations of 1,25- dihydroxyvitamin D3 directly to the colon so its effects on colon carcinogenesis can be assessed in the absence of hypercalcemia. ..
  13. Gut L-Histidine Metabolism and Histamine Signaling in Colonic Neoplasia
    James Versalovic; Fiscal Year: 2013
    ..signaling pathways, and suppression of inflammation may alter predisposition to cancer, specifically colorectal neoplasms. Bacterial genes in the microbiome encode for enzymes that perform biochemical conversion of dietary amino ..
  14. CHARACTERIZATION OF TUMOR SUPPRESSION BY THE APC GENE
    JOANNA LOUISE GRODEN; Fiscal Year: 2010
    ..Our long-term goals are to elucidate the mechanisms and pathways through which APC functions and, by doing so, to contribute to the design of better therapeutic strategies in oncology. ..
  15. Calcium/Vitamin D, Biomarkers & Colon Polyp Prevention
    Roberd Bostick; Fiscal Year: 2009
    ..calcium and vitamin D, in modulating a plausible panel of molecular phenotypic biomarkers of risk for colorectal neoplasia, and determining whether this modulation predicts reduced recurrence of colorectal neoplasms.
  16. Colon Cancer Family Registry Cohort
    NORALANE MOREY LINDOR; Fiscal Year: 2013
    ..Aim 4: Continue to expand the use of the CCFRC and its resources through active collaborations with the larger scientific community. ..
  17. Role of Epigenetic Repression of IRF8 in Tumor Progression/Metastasis
    Kebin Liu; Fiscal Year: 2012
    ..Successful completion of the proposed research will provide a novel strategy for targeting the deadly metastatic human colorectal cancer. ..
  18. Lipid electrophile adduction of Pin1 and effects on substrate binding &activity
    Christopher D Aluise; Fiscal Year: 2013
    ..The proposed research allows for significant insight into the cellular response to Pin1 protein modification as a consequence of lipid peroxidation. ..
  19. T-bet and Tumor Immunity
    LAURIE HOLLIS GLIMCHER; Fiscal Year: 2013
    ....
  20. Regulation of NF-kappaB and IKK by proinflammatory stimuli
    Michael Karin; Fiscal Year: 2013
    ..The proposed studies will be based on a combination of biochemistry, cell biology, and mouse physiology, an integrated approach that was proven very effective in the past. ..
  21. Early life anthropometry, IGF pathway polymorphisms, and colorectal cancer risk
    Esther Wei; Fiscal Year: 2010
    ..g. childhood, young adulthood), with the ultimate goal of generating measurable improvements on the burden of colorectal cancer and other chronic diseases. ..
  22. A Tumor Suppressor Function for the c-Fes Tyrosine Kinase in Colon Cancer
    THOMAS EDWARD SMITHGALL; Fiscal Year: 2012
    ..If c-fes is a true tumor suppressor, then mice lacking c-fes function are expected to develop more severe disease in terms of tumor size, number, and invasiveness. ..
  23. ERalpha Regulation of Intestinal Homeostasis & Tumorigenesis
    Karen A Gould; Fiscal Year: 2010
    ....
  24. Tea Modulation of Colon Carcinogenesis
    Michael Wargovich; Fiscal Year: 2013
    ..Because RXRa loss involves impairment of regulatory gene networks, the impact of green tea reversal of this transcription factor's loss is significant. ..
  25. STAT1 Activation and HPP1 Tumor Suppression
    David Shibata; Fiscal Year: 2013
    ..is a recently identified gene that was initially discovered by virtue of its significant downregulation in colorectal neoplasms derived from patients with Hyperplastic Polyposis...
  26. SPORE IN GASTROINTESTINAL CANCER
    Joel Tepper; Fiscal Year: 2009
    ..Career and Developmental Research Programs are also included. ..
  27. Emory-GA Tech Nanotechnology Center for Personalized an*
    Shuming Nie; Fiscal Year: 2009
    ....
  28. Modulation of junctional signaling by BVES in colorectal carcinoma
    Christopher S Williams; Fiscal Year: 2013
    ..can biomarkers or signatures be identified that can serve as predictors or surrogates of therapeutic efficacy?". ..
  29. A Cohort Study of Sessile Serrated Polyps and Subsequent Colorectal Neoplasia
    Polly A Newcomb; Fiscal Year: 2013
    ....
  30. The Role of PHLPP in Colon Cancer
    Tianyan Gao; Fiscal Year: 2013
    ....
  31. STRAP and Smad 7 Signaling in Colorectal Carcinomas
    Pran K Datta; Fiscal Year: 2013
    ..A better understanding of these mechanisms will help to improve drug development and treatment of this lethal disease. ..
  32. THE TUMOR ANTIGENS TN AND SIALYLTN IN HUMAN COLORECTAL CARCINOMA
    Tongzhong Ju; Fiscal Year: 2013
    ..This project will define the molecular basis for Tn and STn expression in CRC and their potential as novel glycan biomarkers for human colon cancer. ..
  33. A Small Molecule to Activate Cetuximab to Kill K-RAS Mutant Colorectal Tumors
    Barry Jones; Fiscal Year: 2013
    ..If the STTR Phase I study is successful, IND-enabling studies and the initiation of a phase 1 clinical trial of ARI-4175 will be proposed for STTR Phase II. ..
  34. Functions of Protein Tyrosine Kinase 6 in the Gastrointestinal Tract
    Angela L Tyner; Fiscal Year: 2013
    ..Colon cancer becomes deadly after it metastasizes. Understanding the functions of PTK6 in the normal colon and in colon cancer initiation and progression will be critical for evaluating its potential as a therapeuic target. ..
  35. The Role of DNA Methylation in Tumor Maintenance
    Peter W Laird; Fiscal Year: 2013
    ....
  36. Microsatellite Instability and the DNA Mismatch Repair System
    John M Carethers; Fiscal Year: 2013
    ..in the germline of familial colon cancer (Lynch syndrome) as well as inactivated in up to 20% of sporadic colorectal neoplasms due to hypermethylation of one of the components of DNA MMR...
  37. GC-C Agonists: Specific Probes for the Detection of Colorectal Tumors
    Kunwar Shailubhai; Fiscal Year: 2013
    ..Future evaluation of the utility of the probe to detect colorectal metastases may also be warranted. ..
  38. Inhibition of Wnt/B-Catenin Signaling in Colorectal Cancer Therapy
    Wei Chen; Fiscal Year: 2013
    ..Thus accelerate the translational application of niclosamide and its derivatives to improve patient survival. ..
  39. Nanoscale tools for functional studies of cancer-relevant chromatin modifications
    Carlos E Castro; Fiscal Year: 2013
    ..Future work will build on the tools and experimental framework established here to implement DNA origami devices to probe intracellular function of chromatin assemblies. ..
  40. In Vivo Detection of Flat Colorectal Neoplasms with CT Colonography
    JANNE JOHANNES NAPPI; Fiscal Year: 2010
    ..substantially advance the clinical implementation of minimally invasive CTC-based population screening for colorectal neoplasms, thereby increasing patient adherence to colorectal screening guidelines, promoting early prevention of ..
  41. Role of AML1-ETO in Acute Leukemia
    Scott W Hiebert; Fiscal Year: 2013
    ....
  42. Elucidating the Molecular Mechanisms of Ect2 in cytokinesis and oncogenesis
    DANIELLE RYAN COOK; Fiscal Year: 2012
    ..These studies will require my application of a very diverse repertoire of experimental techniques, foster my development into an independent researcher and establish my abilities to do basic and translational cancer research. ..
  43. In vivo role of BTK-mediated inhibition of Wnt/b-catenin signaling during hematop
    Richard James; Fiscal Year: 2011
    ....
  44. Differentiation and Elimination of Chemo-surviving Colon Tumors
    ADHIP N MAJUMDAR; Fiscal Year: 2013
    ..Finally, we will demonstrate that miR-21 regulates [unreadable]-Wnt/catenin and EGFR signaling pathways in colon cancer chemo-resistant cells in vitro. ..
  45. Mitochondrial Genome Analysis to Detect Aggressive Behavior of Premalignant Color
    Felix O Aikhionbare; Fiscal Year: 2013
    ..Results from this study should provide basic knowledge to the development of proper clinical tests for prediction of CRC progression in patients'clinical outcome, which is required for efficacious therapies. ..
  46. Integrated Genomic Discovery and Functional Validation of Colorectal Cancer Loci
    Nancy R Zhang; Fiscal Year: 2013
    ..These studies have implications for generation of novel diagnostic and therapeutic strategies for colon cancer. ..
  47. Mechanisms of Chromatin Transcriptional Regulation
    MICHAEL GUY POIRIER; Fiscal Year: 2013
    ..These studies will provide a foundation for understanding the mechanisms and functional interactions behind chromatin transcriptional regulation and the misregulation of numerous oncogenes. ..
  48. Multimodality approach to hepatic colorectal metastases
    Herbert J Zeh; Fiscal Year: 2013
    ..We believe that this study will provide crucial information about the development of a novel strategy to treat colorectal hepatic metastases. ..
  49. Computerized Detection of Polyps in CT Colonography
    Hiroyuki Yoshida; Fiscal Year: 2013
    ..abstract_text> ..
  50. Eicosanoids and Intestinal Epithelial Growth Regulation
    RAYMOND NELSON DUBOIS; Fiscal Year: 2012
    ..It is becoming clear that just targeting one single molecule will not be as effective as needed to have a significant impact on this disease. ..
  51. Identify and validate novel epigenetic molecular markers for colorectal neoplasm
    Sanford D Markowitz; Fiscal Year: 2013
    ..and have the potential to identify a panel of complementary biomarkers for the early detection of colorectal neoplasms and for enhancing the care of early stage CRC...
  52. MK-STYX: A Requisite Gatekeeper to Mitochondrial Function and Death
    Jeffrey P Mackeigan; Fiscal Year: 2013
    ..We will also determine the prognostic significance of MK-STYX protein levels in a cohort of patients with colorectal cancer. ..
  53. Oral Immune Modulatory Adjuvants for Treatment of Colorectal Carcinoma
    Nejat K Egilmez; Fiscal Year: 2012
    ..e. controlled-release formulations of anti-IL-9 antibody and Masitinib, are evaluated in the same models. If successful, these studies can lead to a new therapeutic paradigm in the management of CRC. ..
  54. ERBB receptors in normal and cancerous colon biology
    David W Threadgill; Fiscal Year: 2012
    ..The use of novel mouse models as proposed in this application has the potential to provide these insights. ..
  55. PTD-Mediated Protein or Drug Delivery for Cancer Therapy
    Victor C Yang; Fiscal Year: 2013
    ....
  56. Inflammatory Differentiation of Colorectal Cancer Among African Americans
    John M Carethers; Fiscal Year: 2013
    ....
  57. Virtual Fly-Over Colonoscopy System for Clinical Test-SBIR Phase 1
    SALWA A ELSHAZLY; Fiscal Year: 2013
    ..Although optical colonoscopy (OC), the current gold standard, detects more than 90% of colorectal neoplasms;it is invasive and can be uncomfortable, inconvenient, and perceived as undesirable by patients...
  58. Modeling causes and consequences of the evolution of cell motility in neoplasms
    CHRISTINA ATHENA AKTIPIS; Fiscal Year: 2012
    ..We will use data from colorectal neoplasms and Barrett's esophagus to test our techniques for estimating cell motility...
  59. Identification of Flat Colorectal Cancer Modifiers
    DAVID JAMES BAUTZ; Fiscal Year: 2013
    ..Understanding the factors that control tumor morphology will aid in identifying candidate biomarkers for their identification and potential new targets for therapeutic intervention. ..
  60. Taming of T-regulatory Cells Following Tumor Irradiation
    CHARLESE GARNETT BENSON; Fiscal Year: 2013
    ..Collectively, we expect the outcomes of this innovative study to lead to novel combinations of immune thera- pies with IR for the control and treatment of cancer. ..
  61. Functional Polymer Matrixes for Site-Specific, Image Guided Drug Delivery
    Agata A Exner; Fiscal Year: 2010
    ....
  62. Tissue-specific Roles of Axin in Canonical Wnt Signaling and Tumorigenesis
    Kathryn V Anderson; Fiscal Year: 2013
    ..The studies will provide a paradigm for how stem/progenitor cells differ from other cells in their sensitivity to Wnt pathway inhibitors, which will define appropriae targets for therapy. ..
  63. Molecular Differences Predicting Tumor Progression in Colorectal Cancer (PQ #14)
    William Schelman; Fiscal Year: 2013
    ..It could also guide novel strategies for chemoprevention and treatment of CRC. ..
  64. MOLECULAR CLONING OF HLA CLASS II TUMOR ANTIGENS
    Dorothee Herlyn; Fiscal Year: 2000
    ..The antigens also may be of diagnostic value. ..
  65. Anti-GM1b IgM for Detection of Localized Prostate Cancer
    Mepur Ravindranath; Fiscal Year: 2005
    ....
  66. ANTIIDIOTYPE VACCINE THERAPY OF HUMAN COLORECTAL CANCER
    MALAYA CHATTERJEE; Fiscal Year: 2002
    ..These studies will be a prelude to clinical trials for CRC patients with autologous DC based anti-Id vaccine and scFv. ..
  67. METASTASIS SPECIFIC CARBOHYDRATE ANTIGENS
    Reuben Lotan; Fiscal Year: 1991
    ..Our long range goal is to determine how the production of sialyl-dimeric LeX antigen is regulated in situ, and to develop methods to reduce the amount, so that the tumor remains non-metastatic during the therapy...
  68. IMPROVING VIRTUAL COLONOSCOPY WITH COMPUTER DETECTION
    Peter Santago; Fiscal Year: 2001
    ..If VC with CAPD proves accurate and efficient in the diagnosis of colorectal polyps, it could evolve into a simple laboratory test, thereby meeting the demand for worldwide colorectal cancer screening. ..
  69. ISOLATION OF OLIGOSACCHARIDES--SUGAR-BINDING PROTEINS
    David Smith; Fiscal Year: 1990
    ..The long term benefits of this research will be to establish an important method for glycolipid structural analyses in the limited numbers of cells that will be encountered in studying glycoconjugate metabolism during embryogenesis...
  70. The Human Colorectal Instabilitome
    Stephen Meltzer; Fiscal Year: 2007
    ..c.i To utilize PCA components to find genes segregating with MSI status, and SAM to identify genes significantly differentially expressed among these three groups. ..
  71. C/EBPbeta Isoform Function & Regulation by Tyrosine Kinases
    Cynthia Zahnow; Fiscal Year: 2009
    ..Functional characterization of the C/EBPB isoforms and the receptor tyrosine kinase pathways that regulate their expression will further our understanding of the molecular basis of mammary development and tumorigenesis. ..
  72. Metabolism and Carcinogenicity of Heterocyclic Amines
    TERRY ZENSER; Fiscal Year: 2007
    ..Determine effect of DSS-induced colitis inflammation) in IQ carcinogenicity. The long-term goal is to understand the role of RNOS on HCA carcinogenesis. ..
  73. GUANYLYL CYCLASE C AS A BI0MARKER FOR COLORECTAL CANCER
    Scott Waldman; Fiscal Year: 2006
    ....
  74. DIETARY PLANT PHENOLICS--EFFECT ON COLONIC BIOMARKERS
    STEVEN SHIFF; Fiscal Year: 1999
    ..These may be integral processes by which NSAIDs inhibit the development of colorectal neoplasms. It is conceivable that other colon cancer chemopreventive agents share these potential mechanisms of ..
  75. The biology of gastrin-ferric ion complexes
    GRAHAM BALDWIN; Fiscal Year: 2009
    ..Recognition that metal ions are essential for the biological activity of NAGs may permit the development of novel therapies for colon cancer. ..